Chesterford Research Park welcomes Uttlesford District Council Cabinet members as part of a special visit organised by INVEST Essex.
Further to Uttlesford District Council’s recent purchase of a 50% share in Chesterford Research Park - to become joint owners alongside Aviva Investors - Cllr Howard Rolfe, Leader of the Council and Cllr Julie Redfern, previously portfolio holder for economic development, visited the Park to tour the facilities of two of Chesterford’s most recent arrivals, Arecor and Evonetix. Both organisations moved to the Park within the last year and received rate relief under the council’s discretionary business rate relief policy – a factor in their decision to locate their facilities at Chesterford.
Arecor is a leader in developing superior biopharmaceuticals through the application of its innovative formulation technology platform, Arestat™. Arecor is leveraging Arestat™ to develop a portfolio of proprietary products to enable improved treatments for diabetes care via the innovative reformulation of approved proteins and peptides. These products will enable next-generation technology and, most importantly, improve quality of life for those with diabetes.
Evonetix was founded in late 2015 with the support of Cambridge Consultants Ltd (CCL) and the entrepreneur and co-founder of Amadeus Capital Partners, Hermann Hauser. The company is developing a novel method of manufacturing DNA molecules, using a microchip-based array.
The resulting economies of scale mean that Evonetix’ technology will be more economical and flexible than the currently available methods, as well as being more comprehensive in its output. Given that DNA is the raw material for the fast-emerging and exciting field of synthetic biology, economical and flexible manufacture is critical.
Cllr Rolfe commented of the visit: “It was a very interesting tour and fascinating to learn more about some of the exciting work happening on the Park. These companies are doing important work and it is encouraging they have chosen Chesterford to continue their operations.
“The Park is an ideal environment for companies to grow and prosper, and it is a major player in the biotechnology, research and development cluster which is so important for the region.”
The visit was organised by INVEST Essex, Essex County Council’s Inward Investment delivery partner, which promotes the opportunities of Essex to businesses across the globe who could benefit from the county’s strategic location, proximity to London and first class transport links.
INVEST Essex works with its commercial partners to ensure that potential investors have the best service and are assisted at all points through their journey to move and set up in the UK. In the cases of Arecor and Evonetix, INVEST Essex worked with both organisations on their choice of location and introduced them to Uttlesford District Council to enable them to take advantage of the Business Development Rate Relief Scheme.
David Rooke, Location Services Director, INVEST Essex said: "We are thrilled to be assisting companies such as Arecor, Evonetix and Enplas find ideal locations from which to do their innovative and ground-breaking work.
“The opportunities for life science companies in Essex is only going to get better as more and more companies see the value of moving to the dynamic London Stansted Cambridge Corridor. We look forward to assisting the current and future companies with their business expansion in Essex."
Chesterford Research Park provides an innovative and flexible environment for both established and early stage biotechnology and pharmaceutical research and development companies. Arecor and Evonetix join an impressive list of current occupiers including AstraZeneca, Charles River Laboratories, Isomerase and Oncologica. The Park’s low-density development, set within 250 acres of impressive parkland, offers ultra-modern and energy efficient laboratory and office space, as well as central ‘hub’ facilities within The Nucleus building – which includes a restaurant, café bar, health and fitness centre, and meeting and conferencing space.
Photo shows – Cllrs Julie Redfern (left) and Howard Rolfe (second left) with Dr Sarah Howell (CEO at Arecor), Joseph Brennan (CSO at Evonetix), and David Russell-Graham and David Rooke from INVEST Essex.
Uttlesford District Council
Daniel Barden, Communications Manager: (01799) 510 442, firstname.lastname@example.org
Chesterford Research Park
Sarah Brereton, Director, Limewash: (01223) 813 560, email@example.com
Arecor is a leader in developing superior biopharmaceuticals through the application of its innovative formulation technology platform. Arecor is leveraging this platform to develop a portfolio of proprietary products enabling improved treatments for diabetes care via the innovative reformulation of approved proteins and peptides. In addition to its internal product portfolio, Arecor partners with leading pharmaceutical and biotech companies to deliver superior reformulations of their proprietary products, which would otherwise not be possible using conventional formulation science. For more information please visit www.arecor.com
Evonetix is a new spin-out company currently incubating in the centre of the world-renowned Cambridge cluster of high-tech and life science organisations. Evonetix is seeking to develop and commercialise a new approach to the synthesis of DNA to facilitate the fast-emerging and exciting field of synthetic biology. For more information please visit www.evonetix.com